Alpha 1 acid glycoprotein (AGP) binds to STI571 and substantially alters its pharmacokinetics in chronic myeloid leukemia (CML) patients.

被引：0
|
作者：
Gambacorti-Passeri, C
Zucchetti, M
Frapolli, R
Russo, D
Rossi, F
Pogliani, E
Corneo, G
Tornaghi, L
Alberti, D
D'Incalci, M
机构：
[1] NCI, Milan, Italy
[2] Osped San Gerardo, Monza, Italy
[3] Mario Negri Inst Pharmacol Res, Milan, Italy
[4] Univ Udine, I-33100 Udine, Italy
[5] Novards Italia, Origgio, Italy
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1305
引用
收藏
页码：309A / 309A
页数：1
相关论文
共 50 条
  • [31] Morphologic and cytogenetic effects of imatinib (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia (CML).
    McNamara, CJ
    Grigg, AP
    Szer, J
    Roberts, A
    Lynda, C
    Hoyt, TR
    Lynch, K
    Juneja, S
    BLOOD, 2001, 98 (11) : 263B - 263B
  • [32] Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Resta, D
    Capdeville, R
    Druker, B
    BLOOD, 2000, 96 (11) : 470A - 470A
  • [33] Skin reactions to imatinib mesylate (STI-571) in patients with chronic myeloid leukemia (CML): Clinical features and histopathology.
    Stone, R
    Galinsky, I
    Haynes, H
    Soiffer, R
    Alyea, E
    Neuberg, D
    Tawa, M
    Antin, J
    Resta, D
    Granter, S
    DeAngelo, D
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [34] Imatinib (STI571) down regulates the angiogenic regulators, vascular endothelial growth factor (VEGF) and interleukine 8 (IL-8) in chronic myeloid leukemia (CML).
    Legros, L
    Jacquel, A
    Mahon, FX
    Belhacen, N
    Pesce, A
    Cassuto, JP
    Auberger, P
    Pages, G
    BLOOD, 2002, 100 (11) : 786A - 786A
  • [35] Quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS study of interferon-alpha plus Ara-C vs imatinib (STI571, Glivec®, Gleevec™).
    Hahn, EA
    Sorensen, MV
    Hudgens, SA
    Glendenning, GA
    BLOOD, 2002, 100 (11) : 94A - 94A
  • [36] A phase II study to determine the safety and antileukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis.
    Sawyers, C
    Hochhaus, A
    Feldman, E
    Goldman, JM
    Miller, C
    Ben-Am, M
    Capdeville, R
    Druker, B
    BLOOD, 2000, 96 (11) : 503A - 503A
  • [37] Effects of STI571 on the development of dendritic cells derived from bone marrow mononuclear cells from patients with chronic myeloid leukemia.
    Jin, J
    Zheng, S
    Tong, XM
    BLOOD, 2005, 106 (11) : 298B - 299B
  • [38] A rapid reduction of Bcr/Abl transcripts is associated with an early cytogenetic response to Glivec® (formerly STI571) in chronic myeloid leukemia in chronic phase (CP):: A study of the Italian cooperative study group on CML (ICSG on CML).
    Martinelli, G
    Pane, F
    Saglio, G
    Alberti, D
    Amabile, M
    Ottaviani, E
    Intrieri, M
    Salvatore, F
    Tiribelli, M
    Rosti, G
    De Vivo, A
    Bonifazi, F
    Trabacchi, E
    Bassi, S
    Russo, D
    Testoni, N
    Ruggeri, D
    Zardini, C
    Giannini, B
    Buonamici, S
    Baccarani, N
    Tura, S
    BLOOD, 2001, 98 (11) : 615A - 615A
  • [39] Safety and tolerability of STI-571 in patients with Ph plus chronic myeloid leukemia in accelerated phase (CML-AP) previously autotransplanted
    Boqué, C
    Encuentra, M
    Peralta, T
    Sala, O
    Moreno, C
    Petit, J
    Sarrà, J
    Grañena, A
    BONE MARROW TRANSPLANTATION, 2002, 29 : S35 - S35
  • [40] Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Giralt, S
    Rios, MB
    Shan, J
    Giles, F
    Thomas, D
    Faderl, S
    de Lima, M
    Arlinghaus, RB
    Garcia-Manero, G
    Issa, JP
    Resta, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
12345